Recent results from the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), in which anti-IL-1β treatment significantly reduced cardiovascular events independent of lipid levels, further support the idea of addressing inflammation as a key process in arresting atherosclerosis with a focus on inflammasomes [2,10,11]. The gene discussed is IL1B; the disease is atherosclerosis.